Get started
Author

Timo T. Myöhänen

Observed names: Myöhänen Timo T, Myöhänen, Timo, Myöhänen, Timo T, T Myöhänen, T. T. Myöhänen, T.T. Myöhänen, TT Myöhänen, Timo Myohanen, Timo Myöhänen, Timo T Myöhänen, Timo T. Myohanen
Observed institutions: University of Helsinki, University of Antwerp, University of Turku, University of Eastern Finland, Washington University in St. Louis, Georgetown University Medical Center, Turku University Hospital
ORCID: 0000-0002-9277-6687
Observed ORCID: 0000-0002-9277-6687
OpenAlex ID: A5078817501
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
2021 · Daniel J. Klionsky, Amal Kamal Abdel-Aziz, et al. · Autophagy · 2,608
PDF
Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent
2019 · Peter Serfozo, Jan Wysocki, et al. · Hypertension · 197
Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice
2010 · Mikko Käenmäki, Anne Tammimäki, et al. · Journal of Neurochemistry · 187
Distribution of catechol‐ O ‐methyltransferase (COMT) proteins and enzymatic activities in wild‐type and soluble COMT deficient mice
2010 · Timo T. Myöhänen, Nadia Schendzielorz, et al. · Journal of Neurochemistry · 108
A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
2012 · TT Myöhänen, MJ Hannula, et al. · British Journal of Pharmacology · 105
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
2021 · Klionsky, Daniel J, Abdel-Aziz, Amal Kamal, et al. · Research at the University of Copenhagen (University of Copenhagen) · 101
The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse
2014 · Mari H. Savolainen, Christopher T. Richie, et al. · Neurobiology of Disease · 95
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
2013 · Yiqin Zuo, Bongkwon Chun, et al. · Kidney International · 88
Issues About the Physiological Functions of Prolyl Oligopeptidase Based on Its Discordant Spatial Association With Substrates and Inconsistencies Among mRNA, Protein Levels, and Enzymatic Activity
2009 · Timo T. Myöhänen, J. Arturo García-Horsman, et al. · Journal of Histochemistry & Cytochemistry · 72
Prolyl Oligopeptidase Enhances α-Synuclein Dimerization via Direct Protein-Protein Interaction
2015 · Mari H. Savolainen, Xu Yan, et al. · Journal of Biological Chemistry · 67
PDF
Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues
2008 · Timo T. Myöhänen, Jarkko I. Venäläinen, et al. · Histochemistry and Cell Biology · 66
Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases
2013 · M.J. Hannula, T.T. Myöhänen, et al. · Neuroscience · 63
Distribution of Immunoreactive Prolyl Oligopeptidase in Human and Rat Brain
2007 · Timo T. Myöhänen, Jarkko I. Venäläinen, et al. · Neurochemical Research · 57
Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters
2008 · Timo T. Myöhänen, Jarkko I. Venäläinen, et al. · The Journal of Comparative Neurology · 54
Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner
2010 · TT Myöhänen, J Tenorio‐Laranga, et al. · British Journal of Pharmacology · 53
PDF
Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A
2019 · Reinis Svarcbahs, Maria Jäntti, et al. · Pharmacological Research · 47
Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and in Ovarian and Colorectal Tumors
2012 · Timo T. Myöhänen, Elisa Pyykkö, et al. · Journal of Histochemistry & Cytochemistry · 47
PDF
Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease
2019 · Tommi Kilpeläinen, Ulrika H. Julku, et al. · Scientific Reports · 46
PDF
Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector–Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain
2016 · Reinis Svarcbahs, Ulrika H. Julku, et al. · Journal of Neuroscience · 46
PDF
New tricks of prolyl oligopeptidase inhibitors – A common drug therapy for several neurodegenerative diseases
2019 · Reinis Svarcbahs, Ulrika Julku, et al. · Biochemical Pharmacology · 42
Analysis of oxysterols and vitamin D metabolites in mouse brain and cell line samples by ultra-high-performance liquid chromatography-atmospheric pressure photoionization–mass spectrometry
2014 · Linda Ahonen, Florian B.R. Maire, et al. · Journal of Chromatography A · 39
Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo
2011 · M. Piltonen, A. Planken, et al. · Neuroscience · 36
A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy
2023 · Tony S. Eteläinen, M. Catarina Silva, et al. · Science Translational Medicine · 35
The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy
2020 · Tommi P. Kilpeläinen, Laura Hellinen, et al. · Biomedicine & Pharmacotherapy · 34
Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo
2018 · Reinis Svarcbahs, Ulrika H. Julku, et al. · Scientific Reports · 34
PDF
Works count: 77
Citation count: 4,821
H-index: 28
I10-index: 48
Year
Topic
Type